Barclays
DFTX icon

Barclays’s Definium Therapeutics DFTX Stock Holding History

Barclays’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$29M Buy
761,867
+711,571
+1,415% +$30M 0.01% 1039
2026
Q2 		$2.37M Buy
50,296
+10,613
+27% +$262K ﹤0.01% 2247
2026
Q1 		$750K Sell
39,683
-143,940
-78% -$2.44M ﹤0.01% 2933
2025
Q4 		$2.46M Buy
183,623
+33,018
+22% +$409K ﹤0.01% 2783
2025
Q3 		$1.78M Sell
150,605
-24,628
-14% -$230K ﹤0.01% 2964
2025
Q2 		$1.14M Buy
175,233
+55,660
+47% +$366K ﹤0.01% 3253
2025
Q1 		$700K Sell
119,573
-35,861
-23% -$257K ﹤0.01% 3315
2024
Q4 		$1.08M Buy
155,434
+19,336
+14% +$133K ﹤0.01% 3329
2024
Q3 		$774K Buy
136,098
+91,271
+204% +$635K ﹤0.01% 3523
2024
Q2 		$323K Buy
44,827
+35,680
+390% +$312K ﹤0.01% 3304
2024
Q1 		$86K Hold
9,147
– – ﹤0.01% 4484
2023
Q4 		$33.5K Hold
9,147
– – ﹤0.01% 4823
2023
Q3 		$28.6K Hold
9,147
– – ﹤0.01% 4073
2023
Q2 		$32.7K Hold
9,147
– – ﹤0.01% 4009
2023
Q1 		$29K Hold
9,147
– – ﹤0.01% 4581
2022
Q4 		$20.1K Sell
9,147
-78
-0.8% -$217 ﹤0.01% 4811
2022
Q3 		$32K Buy
9,225
+7,705
+507% +$74K ﹤0.01% 3915
2022
Q2 		$15K Sell
1,520
-1,965
-56% -$24.9K ﹤0.01% 4502
2022
Q1 		$58K Buy
+3,485
New +$60.5K ﹤0.01% 4055

Other funds holding DFTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays's DFTX Position: Q3 2026 in Review

Barclays increased its Definium Therapeutics (DFTX) stake by 1,415% in Q3 2026, buying an estimated $30M and bringing the position to 761,867 shares worth $29M. The position accounts for 0.01% of the portfolio, ranked #1039.

Barclays first reported a position in DFTX in Q1 2022 and has held it in 19 quarters since. 125 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Barclays held 761,867 shares of Definium Therapeutics worth $29M as of Q3 2026.
  • Barclays bought 711,571 Definium Therapeutics shares in Q3 2026, an estimated $30M.
  • Definium Therapeutics made up 0.01% of Barclays's portfolio in Q3 2026, its #1039 holding.
  • Barclays first reported a position in Definium Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • 125 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.